Bicara Therapeutics (BCAX) Research & Development (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Research & Development of $100000.0 for Q1 2026, down 98.48% year-over-year from $6.6 million in Q1 2025, and up 100.11% quarter-over-quarter from -$92.1 million in Q4 2025.
Bicara Therapeutics (BCAX) Research & Development (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Research & Development history runs 4 years deep, the most recent figure standing at $100000.0 for Q1 2026.
- In Q1 2026, Research & Development fell 98.48% year-over-year to $100000.0; the TTM figure through Mar 2026 stood at -$34.2 million (down 1325.37% YoY), while the FY2024 annual figure was $8.2 million, down 73.15% from the prior year.
- Research & Development for Q1 2026 stood at $100000.0, up from -$92.1 million in the prior quarter.
- The five-year high for Research & Development was $33.0 million in Q3 2025, with the low at -$92.1 million in Q4 2025.
- The 4-year median for Research & Development is $10.5 million (2023), against an average of -$182636.4.
- Peak annual rise in Research & Development reached 130.43% in 2024, while the deepest fall reached 437.94% in 2024.
- Bicara Therapeutics' Research & Development stood at $10.5 million in 2023, then tumbled by 437.94% to -$35.5 million in 2024, then sank by 159.55% to -$92.1 million in 2025, then surged by 100.11% to $100000.0 in 2026.
- Business Quant data shows BCAX's Research & Development at $100000.0 in Q1 2026, -$92.1 million in Q4 2025, and $33.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 45.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.77 Mn |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | -92.10 Mn |
| Sep 30, 2025 | 33.00 Mn |
| Jun 30, 2025 | 24.80 Mn |
| Mar 31, 2025 | 6.58 Mn |
| Dec 31, 2024 | -35.48 Mn |
| Sep 30, 2024 | 15.90 Mn |
| Jun 30, 2024 | 15.80 Mn |
| Mar 31, 2024 | 12.00 Mn |
| Dec 31, 2023 | 10.50 Mn |
| Sep 30, 2023 | 6.90 Mn |